The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a
Zhixia Zhou1, Zhijuan Lin2, Yuqi He3
1Center for Tumor Molecular Biology, Institute for Translational Medicine, Qingdao University, Qingdao 266021, China.
Abstract:
Gastric cancer is one of the most prevalent tumor types in the world. Chemotherapy is the most common choice for cancer treatment. However, chemotherapy resistance and adverse side effects limit its clinical applications. Aberrant expression of long noncoding RNAs (lncRNAs) has been found in various stages of gastric cancer development and progression. In this study, we identified that an oncogenic lncRNA, long intergenic non-protein-coding RNA D63785 (lncR-D63785), is highly expressed in gastric cancer tissues and cells. Silencing of lncR-D63785 inhibited cell proliferation, cell migration and invasion in gastric cancer cell lines and reduced tumor volume and size in mice. We found that the expression of lncR-D63785 was inversely correlated with microRNA 422a (miR-422a) expression, which was involved in the downregulation of expression of myocyte enhancer factor-2D (MEF2D) and drug sensitivity. Knockdown of lncR-D63785 increased the expression of miR-422a and the sensitivity of gastric cancer cells to apoptosis induced by the anticancer drug doxorubicin (DOX). This indicates that lncR-D63785 acts as a competitive endogenous RNA (ceRNA) of miR-422a and promotes chemoresistance by blocking miR-422-dependent suppression of MEF2D. Together, our results suggest that the therapeutic suppression of lncR-D63785 alone or in combination with chemotherapeutic agents may be a promising strategy for treating gastric cancer.
Insights
Targeting long intergenic non-protein-coding RNA D63785 (lncR-D63785) may overcome chemotherapy resistance in gastric cancer. Suppressing lncR-D63785 enhances drug sensitivity and inhibits tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer is a prevalent malignancy with limited treatment options due to chemotherapy resistance and side effects.
- Long noncoding RNAs (lncRNAs) play crucial roles in cancer development and progression.
- Aberrant expression of lncRNAs is implicated in various stages of gastric cancer.
Purpose of the Study:
- To investigate the role of the oncogenic lncRNA, long intergenic non-protein-coding RNA D63785 (lncR-D63785), in gastric cancer.
- To explore the potential of lncR-D63785 as a therapeutic target for overcoming chemoresistance.
Main Methods:
- Quantitative real-time PCR to assess lncR-D63785 and miR-422a expression in gastric cancer tissues and cells.
- In vitro assays (cell proliferation, migration, invasion) and in vivo studies (tumor xenografts in mice) to evaluate the functional role of lncR-D63785.
- Western blotting to determine MEF2D expression.
- Analysis of the regulatory relationship between lncR-D63785, miR-422a, and MEF2D.
Main Results:
- lncR-D63785 was highly expressed in gastric cancer tissues and cells.
- Silencing lncR-D63785 inhibited gastric cancer cell proliferation, migration, invasion, and reduced tumor growth in mice.
- lncR-D63785 acted as a competing endogenous RNA (ceRNA) for miR-422a, leading to the downregulation of MEF2D.
- Knockdown of lncR-D63785 increased miR-422a expression and sensitized gastric cancer cells to doxorubicin (DOX)-induced apoptosis.
Conclusions:
- lncR-D63785 promotes gastric cancer progression and chemoresistance by sponging miR-422a and upregulating MEF2D.
- Therapeutic suppression of lncR-D63785, alone or with chemotherapy, presents a promising strategy for gastric cancer treatment.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Neural Regulation
Hormonal Regulation
Epigenetic Regulation
Regulated mRNA Transport
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...


